Resonance Health (ASX:RHT): A potential game-changer in diagnosing liver fibrosis
Andrew Harrison, Managing Director of Resonance Health (ASX:RHT), spoke with Stocks Down Under about the company’s recent progress in developing an MRI-based diagnostic that can accurately measure liver fibrosis.
Read the full article here: Stocks Down Under
0
likes
•
0
questions
•
0
company answers
Ask a question
Your question will be sent privately to Resonance Health. The company may choose to make this question public.
Investor Q&As
Start the conversation
Ask Resonance Health a question about this update.